Join to View Full Profile
12605 E 16th AveAurora, CO 80045
Phone+1 720-848-0000
Dr. Patel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
University of ColoradoResidency, Internal Medicine, 2005 - 2008
University of Texas Medical Branch School of MedicineClass of 2005
Certifications & Licensure
OH State Medical License 2025 - 2027
IA State Medical License 2025 - 2026
ID State Medical License 2025 - 2026
IL State Medical License 2025 - 2026
TN State Medical License 2023 - 2026
MT State Medical License Active through 2026
ND State Medical License 2025 - 2026
American Board of Internal Medicine Medical Oncology- Join now to see all
Clinical Trials
- A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Start of enrollment: 2011 Dec 01
- PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
- Doxycycline, Temozolomide and Ipilimumab in Melanoma Start of enrollment: 2012 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Design considerations for randomized comparisons of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy when tumor measurement schedules do not align (SWOG ...Megan Othus, Elad Sharon, Michael C Wu, Vernon K Sondak, Antoni Ribas
Clinical Trials. 2025-03-18 - Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary.Sapna P Patel, Rahul A Sheth, Christina Davis, Theresa Medina
Journal of Clinical Oncology. 2025-03-10 - Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial.Mohamed A Gouda, Abdulrazzak Zarifa, Yali Yang, Bettzy Stephen, Serdar A Gurses
Journal of Immunotherapy and Precision Oncology. 2025-02-01
Journal Articles
- Author Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaJanice N Cormier, Ehab Hanna, Padmanee Sharma, Jennifer A Wargo, Isabella C Glitza, Sapna P Patel, Adi Diab, Jeffrey E Lee, Richard Royal, Randal Weber, Patrick Hwu, J..., Nature
- Publisher Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaScott Woodman, Alexander J Lazar, Michael A Davies, Neil Gross, Sapna P Patel, Isabella C Glitza, Ehab Hanna, Stephen Y Lai, Richard Ehlers, Amy Hessel, Padmanee Sharm..., Nature
- Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaRichard Royal, Alexander J Lazar, Adi Diab, Sapna P Patel, Jeffrey E Lee, Padmanee Sharma, Patrick Hwu, Randal Weber, Jeffrey Gershenwald, Carol Lewis, Richard Ehlers,..., Nature
Press Mentions
Melanoma Survivor: Protect Your SkinMarch 19th, 2019
Major Pathologic Response to Neoadjuvant Pembrolizumab in Advanced Melanoma Trial Exceeds 50%October 25th, 2023- Pembrolizumab Trial in Advanced Melanoma Shows Major Pathological Response Exceeding 50%October 25th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
